Last updated: 2026-10-02 11:41:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
AnaptysBio, Inc. (ANAB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $48.62, with a market capitalization of $1.50B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $29.48 to $73.30. This page covers its latest market performance, valuation, price trends and company information.
$1.50B | |
$49.94 | |
$134.00 | |
$10.00 | |
$50.26 | |
439.94K | |
576.22K | |
-- | |
$73.30 | |
$29.48 | |
-- | |
-- |
AnaptysBio, Inc. (ANAB) is trading at $50.00 in pre-market trading as of 2026-10-01 23:31:00, down 0.52% ($0.26) from the previous close of $50.26
Pre-market trading shows how investors are pricing ANAB before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, AnaptysBio, Inc. (ANAB) moved from $50.77 to $48.62, representing a decline of 4.23% ($2.15).
The stock traded between $48.04 and $53.93 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 666.91 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 43.7%
ANAB is currently trading at $48.62, placing it 43.7% of the way from its 52-week low of $29.48 to its 52-week high of $73.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AnaptysBio, Inc. (ANAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.